tradingkey.logo

Innocare Pharma Announces Achievement Of Primary Endpoint In Phase 2B Study Of Orelabrutinib,

ReutersDec 15, 2025 12:23 PM

- Zenas Biopharma Inc ZBIO.O:

  • ZENAS BIOPHARMA’S PARTNER, INNOCARE PHARMA, ANNOUNCES ACHIEVEMENT OF PRIMARY ENDPOINT IN PHASE 2B STUDY OF ORELABRUTINIB, A BTK INHIBITOR, FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI